New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2012
08:03 EDTOGXIOncoGenex reports positive data for compound OGX-427
OncoGenex announced that preclinical data utilizing their pipeline compound OGX-427 was presented at the 27th Annual EAU Congress.This preclinical study, along with previously reported preclinical data, further demonstrated the potential of OGX-427 to augment anti-cancer therapies and delay tumor progression. The study showed that when Hsp27 was decreased via OGX-427 treatment, the effect of the Hsp90 inhibitors was enhanced and tumor cell death was observed. The authors concluded OGX-427 in combination with Hsp90 inhibitors potentiated the effects of Hsp90, delayed tumor growth and prolonged survival in murine prostate cancer models.
News For OGXI From The Last 14 Days
Check below for free stories on OGXI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
06:32 EDTOGXIOncoGenex completes patient enrollment in Phase 3 AFFINITY trial
OncoGenex Pharmaceuticals announced that patient enrollment has been completed in the Phase 3 AFFINITY trial. The international, randomized, open-label Phase 3 AFFINITY trial is designed to evaluate the potential of custirsen to improve survival outcomes in approximately 630 men with metastatic castrate-resistant prostate cancer. Patients have been randomized to receive second-line Jevtana and prednisone with or without custirsen.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use